BRIEF-Cyclacel Pharmaceuticals reports updated data from DNA damage response program on seliciclib, sapacitabine combination
June 06, 2016 at 10:28 AM EDT
* Cyclacel pharmaceuticals reports updated data from dna damage response program on seliciclib and sapacitabine combination in patients with solid tumors